Medical Advocates
Pegylated Interferon Alfa-2a (Pegasys)
  HIV/HCV Indications

 General Reports
 Viral Dynamics
 Adverse Events
 Efficacy






 		  
Peginterferon Alfa-2a Main Page   Main New/Newsworthy Home Page
Last Update:  October 22, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
     
     Journal Papers, Abstracts, and Commentaries
 
   
Peg-interferon alfa-2a and highly active antiretroviral drug therapy on hepatitis C patients
with AIDS.
Zhang RF, Sun HQ, Huang Q, et al 
Zhonghua Gan Zang Bing Za Zhi. 2007 Oct;15(10):734-7
 Abstract

Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV–focus on
pegylated interferon-alpha.
 Zoller H, Vogel W.
 Int J Nanomedicine. 2006;1(4):399-409
 Abstract
 
       Conference Reports, Abstracts, and Posters 
 
 
 

POSTER
 Does the Choice of NRTI Have a Significant Influence on the Outcome of peg-IFN plus Ribavirin
among HIV/HCV-co-infected Patients?
 A Moreno, C Quereda, A Muriel, et al
(15th CROI)
 PDF Poster     Abstract
Viral Dynamics
     
     Journal Papers, Abstracts, and Commentaries
 
 
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect
viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus
ribavirin () for 16 or 24 weeks.
 Rodriguez-Torres M, Govindarajan S, et al
 Liver Int. 2008 Aug 14.
 Abstract

A WEEK IN REVIEW FEATURED REPORT
 Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients
on peginterferon-alfa-2a.
 Nasta P, Gatti F, Puoti M,et al  
AIDS. 2008 Apr 23;22(7):857-61
 Abstract
 
       Conference Reports, Abstracts, and Posters 
 
 
Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated
interferon -2a or -2b
 E. Vispo, P. Barreiro, S. Rodriguez-Novoa, et al 
(XVII International AIDS Conference)
 Abstract
 
Hepatitis C viral kinetics during treatment with weekly versus twice weekly peg IFN-alpha-2a
in HIV/HCV co-infected patients
 Polis M, Sachau W, O’Shea M, et al
(4th IAS Conference)
 Abstract
 
HOMA-IR Is a Strong Predictor of Rapid Virologic Response in HIV/HCV-co-infected Patients
Treated with Pegylated Interferon-alpha 2a and Ribavirin
 P Nasta, M Puoti, F Gatti, et al
(14 CROI)
 Abstract

Histological response to peginterferon alfa-2a (40KD) (PEGASYS®) plus
ribavirin (COPEGUS®) in HIV-HCV co-infected patients with bridging fibrosis
or cirrhosis in the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT)
 Lissen E., Clumeck N., Sola R., et al
(3rd IAS)
 Abstract

Predictability of Virologic Response at Week 4 and 12 of Peginterferon Alfa-2a (40KD) Plus Ribavirin
(RBV) Therapy in HIV-HCV Co-Infection: AIDS PEGASYS Ribavirin International Co-Infection Trial
(APRICOT)
 F.J. TORRIANI, M. RODRIGUEZ-TORRES , E. LISSEN , et al 
(45 ICAAC)
 Abstract
Adverse Events
 
     Journal Papers, Abstracts, and Commentaries
 
 
Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients
treated with pegylated interferon plus ribavirin.
 Núñez M, Ocampo A, Aguirrebengoa K, et al
J Viral Hepat. 2007 Dec 21
Abstract

Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type
1-coinfected subjects.
Behler CM, Vittinghoff E, Lin F, et al
Clin Infect Dis. 2007 May 15;44(10):1375-83.
 Abstract
 
       Conference Reports, Abstracts, and Posters 
 
 
Predictors of insulin resistance (IR) in HIV/HCV co-infected patients treated with pegylated
interferon alpha 2-a (Peg/IFN) and ribavirin (RBV)
 Matti A, Nasta P, Borghi F, et al
 (4th IAS Conference)
 Abstract

Neuropsychological disturbances (NPS) predict a lower rate of rapid virologic response (RVR)
and early virologic response (EVR) in HIV/HCV co-infected patients treated with pegylated
interferon alpha 2-a (Peg/IFN) and ribavirin (RBV)
 Nasta P, Antonelli S, Compostella S, et al
 (4th IAS Conference)
 Abstract
Efficacy
 
Peg Interferon alfa-2a vs Peg Interferon alfa-2a/Ribavirin
 
     Journal Papers, Abstracts, and Commentaries
 
 
Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus.
 Marucco DA, Veronese L, de Requena DG, et al  
J Antimicrob Chemother. 2007 Jan 9;
 Abstract
 
Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded,
randomized multicenter trial.
 Khalili M, Bernstein D, Lentz E, et al
 Dig Dis Sci. 2005 Jun;50(6):1148-55.
 Abstract
 

      Conference Reports, Abstracts, and Posters 

 
HCV relapses upon completion of peg-interferon plus ribavirin in HIV-infected patients: rate, timing
and predictors
 P. Barreiro, M. Nuñez, I. Santos, et al 
(XVII International AIDS Conference)
 Abstract

Comparison of Pegylated Interferons Alfa-2a and Alfa-2b in HCV/HIV-1 Co-Infected Patients
 J. SLIM, J.P. FALLON, N. SCANGARELLO, S.M. SMITH; 
(45 ICAAC)
Abstract
 
Peg Interferon alfa-2a/Ribavirin

     Journal Papers, Abstracts, and Commentaries

 
Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD)
Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection.
Opravil M, Sasadeusz J, Cooper DA, et al
J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):36-49.
 Abstract
 
Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected
patients who failed previous IFN based therapy.
 Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al 
J Clin Virol. 2006 Oct 23
 Abstract

Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and
hepatitis C virus co-infection.
 Hornberger J, Torriani FJ, Dieterich DT, et al
 J Clin Virol. 2006 Jun 7;
 Abstract

      Conference Reports, Abstracts, and Posters 

 
Efficacy of the treatment with peginterferon alfa-2a or peginterferon alfa-2b in co-infected patients treated at
the reference center for AIDS in Santos, SP, Brazil
 M. Caseiro, S.O. Costa, M.H. Ventura, et al
(XVII International AIDS Conference)
 Abstract
 
Pegylated interferon alfa-2a (PEG-IFN) + ribavirin (RBV) in HIV infected individuals within the
Australian Trial of Acute Hepatitis C (ATAHC) achieves end of treatment response (ETR) in over
80% of individuals
 Matthews G, Hellard M, Sasadeusz J, et al
 (4th IAS Conference)
 Abstract
 
A phase II open-label pilot trial of the antiretroviral activity, safety, and tolerability of
pegylated interferon-α-2a (40KD) (PegIFN) in HIV-1 infected subjects – ACTG 5192
 Asmuth D, Chan E, Cai T , et al
 (4th IAS Conference)
 Abstract
 
Causes of Premature Discontinuation in HIV/HCV Co-infected Patients in PRESCO, a Large Trial
of Treatment with Pegylated Interferon plus Weight-based Ribavirin
 V Soriano, E Losada, I San Joaquin, et al
 (14 CROI)
 Abstract
 
POSTER
 Antiretroviral Regimens including Tenofovir or Stavudine + Lamivudine as NRTI Backbone Are
Associated with Higher Sustained Virological Response Rate to Pegylated Interferon and Ribavirin
Treatment in HIV/HCV-co-infected Patients
 JA Mira, R Carrillo-Gómez, A Gutierrez-Valencia, et al
(14 CROI)
 PDF Poster     Abstract
 
Cut-off Values of Ribavirin Trough Concentration for Sustained Virological Response and for
Hematological Toxicity in HCV/HIV-co-infected Patients Treated with RBV and Pegylated Interferon
 DA Marucco, D Gonzalez de Requena, L Veronese, et al
(14 CROI)
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
16 or 24 weeks of peginterferon alfa-2a (40kd) (pegasys®) plus ribavirin (rbv) (copegus®) in
patients with hcv genotype 2 or 3 and bridging fibrosis or cirrhosis: results from a large, randomised
multinational study (accelerate)
Zeuzem S., Pappas S., Nyberg L., et al 
(12th International Symposium on Viral Hepatitis and Liver Disease)
 Abstract
 
Baseline HCV Genotype 1 RNA Concentration: Relationships with Sustained Virologic
Response to Peginterferon alfa-2a Plus Ribavirin and with Demographic Characteristics
 J. TICEHURST, J. RAKELA , H. BODENHEIMER, et al 
(45 ICAAC)
Abstract
 
Treatment Exposure and Sustained Virologic Response (SVR) in Genotype 1 Patients Treated with
Peginterferon alfa-2a (40KD) (PEG IFNα2a)+ Ribavirin (RBV) in APRICOT (AIDS PEGASYS Ribavirin
International Co-Infection Trial)
 M. OPRAVIL, F. TORRIANI , J. SASADEUSZ,  et al
(45 ICAAC)
Abstract
 
Determinants of Early Anti-HIV Effect of Pegylated interferon alfa 2a (PegINF)
and Ribavirin (RBV) in Antiretroviral Therapy (ART)-Free Coinfected HIV/HCV Patients
 L. VERONESE, D. AGUILAR, D. GONZALEZ DE REQUENA, et al  
(45 ICAAC)
Abstract
 
Impact of Growth Factors (GF) on Treatment Outcomes in Patients with HIV-HCV Co-Infection in
the AIDS PEGASYS Ribavirin (RBV) International Co-Infection Trial (APRICOT)
 M. SULKOWSKI, N. BRÄU , F. J. TORRIANI , et al 
(45 ICAAC)
Abstract
 
Treatment Exposure and Sustained Virologic Response (SVR) in Genotype 1 Patients Treated with
Peginterferon alfa-2a (40KD) (PEG IFNα2a)+ Ribavirin (RBV) in APRICOT (AIDS PEGASYS Ribavirin
International Co-Infection Trial)
 M. OPRAVIL, F. TORRIANI , J. SASADEUSZ,  et al  
(45 ICAAC)
Abstract
 
Predictability of Virologic Response at Week 4 and 12 of Peginterferon Alfa-2a (40KD) Plus Ribavirin
(RBV) Therapy in HIV-HCV Co-Infection: AIDS PEGASYS Ribavirin International Co-Infection Trial
(APRICOT)
 F.J. TORRIANI, M. RODRIGUEZ-TORRES , E. LISSEN , et al 
(45 ICAAC)
Abstract
 
Impact of Growth Factors (GF) on Treatment Outcomes in Patients with HIV-HCV Co-Infection in
the AIDS PEGASYS Ribavirin (RBV) International Co-Infection Trial (APRICOT)
 M. SULKOWSKI, N. BRÄU , F. J. TORRIANI , et al 
(45 ICAAC)
Abstract
 
Nadir CD4% Independently Predicts Immunological Failure in Antiretroviral Therapy (ART)
Free HIV/HCV Coinfected Subjects Treated with Pegylated Interferon alfa (PegINF) and
Ribavirin (RBV)
 D. AGUILAR, L. VERONESE, D. GONZALEZ DE REQUENA, et al
(45 ICAAC)
Abstract
 
Determinants of Early Anti-HIV Effect of Pegylated interferon alfa 2a (PegINF)
and Ribavirin (RBV) in Antiretroviral Therapy (ART)-Free Coinfected HIV/HCV Patients
 L. VERONESE, D. AGUILAR, D. GONZALEZ DE REQUENA, et al  
(45 ICAAC)
Abstract
 
Patients with HCV/HIV co-infection achieving a sustained virological response following
HCV treatment with peginterferon alfa-2a (Pegasys®) plus ribavirin (Copegus®) have i
mproved health related quality of life
 D T Dieterich, M Rodriguez-Torres, J K Rockstroh, et al
(15IAC)
 Abstract
 
  HCV-related factors but not HIV-related factors at baseline predict the response to
treatment with peginterferon alfa-2a (40KD) (Pegasys) plus ribavirin (Copegus) in patients
with HCV/HIV co-infection: Predictor analysis from the APRICOT study
D Cooper, FJ Torriani, M Rodriguez-Torres, et al
 (45th ICAAC)
 Abstract
 
  Patients with HCV/HIV co-infection achieving a sustained virological response following
HCV treatment with peginterferon alfa-2a (Pegasys®) plus ribavirin (Copegus®) have improved
health related quality of life
DT Dieterich, M Rodriguez-Torres, JK Rockstroh, et al
 (45th ICAAC)
 Abstract
 
  Moderate dose of PegInterferon alfa-2b in combination with ribavirin in the treatment of HCV
patients with or without HIV
 C Sarmento, A Horta, H Coelho, O Vasconcelos, et al.
 (45th ICAAC)
Abstract
 
  Safety of peginterferon alfa-2a (PEGASYS) 180 mcg weekly plus ribavirin (RBV) 800 mg daily
in HIV/HCV coinfection compared to HCV monoinfection
N Bräu, FJ Torriani, M Rodriguez-Torres, et al
 (45th ICAAC)
 Abstract
 
  Predictability of sustained virological response (SVR) in patients with HCV/HIV co-infection during
combination therapy with peginterferon alfa-2A (40KD) (Pegasys®) plus ribavirin (Copegus®) in the
APRICOT trial
M Rodriguez-Torres, FJ Torriani, E Lissen, et al
 (45th ICAAC)
Abstract
 
  PegInterferon-alfa2a plus ribavirin in HIV/HCV-coinfected patients: early assessment of response in
the PRESCO trial
 M Núñez, P Barreiro, A Ocampo. et al
 (45th ICAAC)
Abstract
 
  Sustained Virologic Response (SVR) in HIV-HCV Co-infected Patients with HCV Genotype 1(G1)
Infection who have a Rapid Virological Response (RVR) at Week 4 of Treatment with Peginterferon
Alfa-2a (40KD) (PEG IFNa-2a, PEGASYS®) Plus Ribavirin (RBV, COPEGUS®): AIDS PEGASYS
Ribavirin International Co-infection Trial (APRICOT)
 D Dieterich, F Duff, M Sulkowski, et al 
(13 CROI)
 Abstract
 
  Efficacy of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®)
in patients with HCV genotype 4 infection in the AIDS PEGASYS Ribavirin
International Co-infection Trial (APRICOT)
 Soriano V., Mendes-Correa M.C., Gonçales Jr. F.L., et al
 (3rd IAS)
 Abstract
 
Final Results of APRICOT: A Randomized, Partially Blinded, International Trial Evaluating |
Peginterferon-alfa-2a + Ribavirin vs Interferon-alfa-2a + Ribavirin in the Treatment of HCV in
HIV/HCV Co-infection
 FJ Torriani, J Rockstroh, M Rodriguez-Torres, et al
 (11CROI)
 Abstract
 
Peg Interferon alfa-2a/Ribavirin vs Interferon alfa-2a/Ribavirin

     Journal Papers, Abstracts, and Commentaries

  Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C
in HIV-coinfected persons.
Chung RT, Andersen J, Volberding P, et al
N Engl J Med. 2004 Jul 29;351(5):451-9.
 Abstract
 
       Conference Reports, Abstracts, and Posters 
 
  Histological response to peginterferon alfa-2a (40KD) (PEGASYS®) plus
ribavirin (COPEGUS®) in HIV-HCV co-infected patients with bridging fibrosis
or cirrhosis in the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT)
 Lissen E., Clumeck N., Sola R., et al
(3rd IAS)
 Abstract

Peginterferon Alfa-2a Main Page   Main New/Newsworthy Home Page

Pegylated Interferon Alfa-2a
HIV/HCV Indications